Pacific Biosciences Of California, Inc. · NASDAQ:PACB
Pacific Biosciences Of California — Q2 2026 Earnings Presentation
17 slides from Pacific Biosciences Of California's earnings presentation, Aug 5, 2026
Slide 1: Q2 2026 Earnings Presentation
Q2 2026 Earnings Presentation August 5, 2026 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic net income and loss per share, net income, net loss, gross margins, gross profit (loss), and operating expenses in addition to, and not as a substitute for, or becaus
Slide 3: Positioning PacBio for the Next Phase of Growth
Positioning PacBio for the Next Phase of Growth Mark Van Oene President and Chief Executive Officer • Five years as PacBio's Chief Operating Officer • Led R&D, Operations and Commercial organizations • Drove Revio, Vega and SPRQ-Nx development • Deep knowledge of PacBio and the genomics and clinical
Slide 4: Q2 2026 Summary
Q2 2026 Summary $39.0M $12.8M Instrument Revenue Total Revenue 20 Revio Systems 26 Vega Systems ~60% to new customers ~80% to new customers $20.1M Consumable Revenue Cumulative Revio and Vega Shipments • Record clinical & hospital sales • ~$202,000 annualized Revio pull- through 4
Slide 5: Q2 2026 revenue breakdown
Q2 2026 revenue breakdown Product & Service Regional Asia Pacific $7.0M Consumables $20.1M Instruments Americas $12.8M $39.0M $17.6M $39.0M EMEA $14.4M Service + Other $6.1M 5
Slide 6: SPRQ-Nx is designed to deliver high-quality HiFi at a highly competitive price point
SPRQ-Nx is designed to deliver high-quality HiFi at a highly competitive price point Executed full launch in Designed to deliver among the most complete view of the genome with U.S list price of $345 per genome May 2026 Multi-use SMRT cells One-third of install base opted Intended to reduce the cost
Slide 7: New publications highlight growing validation of our differentiated technology
New publications highlight growing validation of our differentiated technology Recent publication in Article entitled “Clinical Long-Read Genome Sequencing for Rare-Disease Diagnostics” proves HiFi improves diagnostic NEJM demonstrates HiFi yield while also simplifying the laboratory workflow, as a
Slide 8: HiFi Solves Sub-fertility Consortium releases preprint from first major study in Asia Pacific
HiFi Solves Sub-fertility Consortium releases preprint from first major study in Asia Pacific ✓ Multinational study investigating unexplained subfertility and recurrent pregnancy loss ✓ Comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seekin
Slide 9: Q2 2026 non-GAAP financial highlights
Q2 2026 non-GAAP financial highlights Non-GAAP1 Measures Q2 2026 Q2 2025 Non-GAAP Gross Profit $13.9M $15.2M Non-GAAP Gross Margin 36% 38% Non-GAAP Operating Expenses $56.1M $58.1M Non-GAAP Net Loss $41.9M $40.0M Non-GAAP Basic Net Loss Per Share $0.14 $0.13 December 31, June 30, 2026 March 31, 2026
Slide 10: Updating 2026 guidance
Updating 2026 guidance Revenue $155M - $165M (3%) - +3% y/y growth Non-GAAP Gross Margin Non-GAAP Operating Expenses 35% - 37% $215M - $220M vs. 40% in 2025 vs. $230M in 2025 10
Slide 11: 2026 focus areas
2026 focus areas Dramatically improve the economics of HiFi through SPRQ-Nx with multi-use SMRT cells Accelerate clinical adoption across rare disease, oncology, and carrier screening Enable discovery through large-scale studies with HiFi’s rich data and high-throughput capabilities Empower next-gen
Slide 12: Enabling the promise of genomics to better human health
Our mission Enabling the promise of genomics to better human health Creating the world’s most advanced sequencing technologies 12
Slide 13: Appendix
fa oO = ® Q. Q < 13, PacBi@
Slide 14: Condensed Consolidated Statements of Operations
PacBi@ @ excep per share amounts) i : : | | Service and other revenue 6057 sos4 683 Cost of Revenue: Cost of service and other revenue 5242 482 3 8 ‘Loss on purchase commitment ' ' 2 Gross profit i 3 A Research and development E i i Settlement charges!” ' z 3 ' ‘Amortization of acquired intangible a
Slide 15: Unaudited Condensed Consolidated Balance Sheets
PacBi@ Pacific Biosciences of California, Inc. Unaudited Condensed Consolidated Balance Sheets June 30, December 31, (in thousands) 2026 3 Accounts receivable, net 31,104 i Prepaid expenses and other current assets © E 10,793 Operating lease right-of-use assets, net 40,331 41,695 Intangible assets,
Slide 16: Non-GAAP reconciliation
PacBi@ meas, a, crept pe i | i F i charge intr vtec conangerconarton - en, ‘Amoraatan of sqarediangble sets ane ame a6 & ane ‘igen shred sts © on i i i f i i enabar net ose Fy 8 8 asm sassy § orm 8 ese) ‘aap bat neti ger owe sew sem sews em sam Seale omg - cas - ome - ‘ccton et shred assets © - co -
Slide 17: www.pacb.com
www.pacb.com Research use only. Not for use in diagnostic procedures. © 2024 Pacific Biosciences of California, Inc. (“PacBio”). All rights reserved. Information in this document is subject to change without notice. PacBio assumes no responsibility for any errors or omissions in this document. Certa
Pacific Biosciences of California — Q2 2026 Earnings Presentation on 6ix